🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

503 results for “Regeneron” Clear

  1. REGN3470-3471-3479

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  2. REGN3500

    Regeneron UK Limited

    Asthma, Allergic

    phase 1 small molecule completed

    1 trial

  3. REGN3500

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  4. REGN3500

    Regeneron UK Limited

    Asthma

    phase 1 small molecule completed

    1 trial

  5. REGN3767

    Regeneron UK Limited

    Malignancies

    phase 1 small molecule completed

    1 trial

  6. REGN3918

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  7. REGN421(SAR153192)

    Regeneron UK Limited

    Advanced Solid Malignancies

    phase 1 small molecule completed

    1 trial

  8. REGN4461

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  9. REGN4659

    Regeneron UK Limited

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule terminated

    1 trial

  10. REGN475 (SAR164877)

    Regeneron UK Limited

    Healthy

    phase 1 mab completed

    1 trial

  11. REGN5069

    Regeneron UK Limited

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  12. REGN5093-M114

    Regeneron UK Limited

    Advanced NSCLC

    phase 1 small molecule terminated

    1 trial

  13. REGN5381

    Regeneron UK Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  14. REGN5678

    Regeneron UK Limited

    Prostate Cancer

    phase 1 small molecule active

    1 trial

  15. REGN5713-5714-5715

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  16. REGN6490

    Regeneron UK Limited

    Healthy Volunteer

    phase 1 small molecule terminated

    2 trials

  17. REGN6569

    Regeneron UK Limited

    Squamous Cell Carcinoma of Head and Neck

    phase 1 small molecule terminated

    1 trial

  18. REGN668

    Regeneron UK Limited

    Healthy

    phase 1 mab completed

    1 trial

  19. REGN668

    Regeneron UK Limited

    Dermatitis

    phase 1 mab completed

    1 trial

  20. REGN668: Injection Rate 1

    Regeneron UK Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  21. REGN7257

    Regeneron UK Limited

    Severe Aplastic Anemia (SAA)

    phase 1 small molecule terminated

    1 trial

  22. REGN727

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  23. REGN727

    Regeneron UK Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  24. REGN727(SAR236553)

    Regeneron UK Limited

    Hypercholesterolemia

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources